Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Singapore · Research

Singapore AURs guide lecanemab use in early Alzheimer’s disease

Human idea, AI creation20 Nov 2026Neurology
Share

Singapore physicians should prescribe lecanemab only for patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia after confirming amyloid pathology, with careful monitoring for ARIA, especially in APOEε4 carriers.

Abstract illustration of a human brain composed of blue and gold organic shapes and neural connections
Image: human idea, AI creation

Background

Lecanemab is a monoclonal antibody that targets β‑amyloid oligomeric species, protofibrils, and insoluble fibrils and has received approval for Alzheimer’s disease in Singapore, according to the phase 3 Clarity AD trial.

Appropriate Use Recommendations

  • The lecanemab Appropriate Use Recommendations (AURs) set out how Singapore physicians should select patients: locally validated cognitive testing, confirmation of amyloid pathology, a baseline brain MRI and APOE ε4 genotyping. They also cover how to stratify ARIA risk, monitor treatment, manage infusion reactions and decide when to stop treatment. A checklist in the paper covers evaluation of candidates, safety monitoring and management of adverse events.
  • The AURs help Singapore physicians identify suitable candidates for lecanemab, weigh risks and benefits for each individual, and guide safety monitoring during treatment.

Risk Management

APOE ε4 carriers face a higher chance of developing amyloid‑related imaging abnormalities (ARIA) and require additional caution. Routine surveillance for ARIA symptoms and follow‑up MRI scans are recommended throughout treatment. Guidance is also provided for managing infusion‑related reactions and for situations that warrant discontinuation of lecanemab.

Future Directions

A Singapore‑specific registry is planned to collect long‑term safety and efficacy data and to support a consensus‑driven framework for optimising lecanemab use in the local population.

References

  1. Chen CL, Kandiah N, Kumar S, Lee KE, Liew TM, Ng ASL, et al. Lecanemab in Singapore: Appropriate use recommendations for early Alzheimer's disease. Ann Acad Med Singap. 2026. doi:10.47102/annals-acadmedsg.2026185. PMID: 42995156. PubMed

Medically reviewed by Stijn van den Borne on 20 Nov 2026